Trial for People With Established Type 2 Diabetes During Ramadan

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Dual therapy with metformin and Liraglutide is more effective at helping people with established Type 2 Diabetes Mellitus (T2DM) observing Ramadan achieve a triple composite endpoint of weight reduction and/or maintenance and improved HaemaglobinA1c (HbA1c) and no severe hypoglycaemic events.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Leicester
• Collaborators: University Hospital Birmingham; University Hospitals, Leicester
• Treatments: Benzocaine; Liraglutide; Metformin; Pioglitazone

Criteria

Inclusion Criteria:

• Individuals ≥ 18 years old with established T2DM on metformin only

• or dual therapy of metformin plus a sulphonylurea or pioglitazone

• with a HbA1c between 7 - 11 % if on monotherapy and between 6.5 - 12% if on dual therapy

Exclusion Criteria:

• Are pregnant or breast feeding

• Suffer from terminal illness

• Have significant renal or liver impairment

• Are unable to provide informed consent

• Have severe and enduring mental health problems

• Are not primarily responsible for their own care

• Are receiving insulin therapy

• Type 1 diabetes